$27.40
▲ +1.3% Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says
Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target
Aktis: Q2 Earnings Snapshot
Overview
52-week range
$15
$34
65% of range
Avg surprise (last 1)
-22.6%
Avg reaction (last 1)
-1.8%
0% positive
Latest IV / EM
127%
EM ±19.8% · $25 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.44 | — | — | — | — | financials |
| Mon May 11, 2026 | Mar/2026 | $-0.38 | $-0.31 | -22.6% | — | -1.8% | earnings |
| Mon Jun 30, 2025 | Jun 2025 | $-22.39 | — | — | — | — | financials |
| Mon Mar 31, 2025 | Mar 2025 | $-18.60 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | $3M | $3M | — | $2M | $1M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-29M | $-23M | — | $-21M | $-18M |
| Net income | $-24M | $-18M | — | $-18M | $-15M |
| EPS (diluted) | $-0.44 | $-0.38 | — | $-22.39 | $-18.60 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $82M | $372M | $38M | $110M | $58M |
| Inventory | — | — | — | — | — |
| Total current assets | $525M | $544M | $230M | — | — |
| Total assets | $558M | $577M | $265M | — | — |
| Long-term debt | — | — | — | — | — |
| Total liabilities | $73M | $71M | $78M | — | — |
| Total equity | $485M | $506M | $-146M | $-118M | $-102M |